Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05360056 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring Following Hospital Discharge
A NA study of Type 2 Diabetes, sponsored by Kathleen Dungan.
- Active
- Registry status
- NA
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT05360056: Active NA study of Type 2 Diabetes, sponsored by Kathleen Dungan.
NCT05360056 is a NA study of Type 2 Diabetes that is active but no longer recruiting, run by Kathleen Dungan. The registered enrollment target is 108 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05360056, a NA study of Type 2 Diabetes, is active but no longer recruiting, sponsored by Kathleen Dungan.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.
Primary Outcome
Change in %time in range between 70-180 mg/dl from 2 weeks to 12 weeks.
Conditions Studied
Interventions
- DEVICE DexCom G6
Study Locations (1)
Ohio
- The Ohio State University Medical Center - Outpatient Care East - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2022-04-26 |
| Est. Completion | 2025-12 |
| Phase | NA |
What the registry record for NCT05360056 still lists
NCT05360056 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which DexCom G6 is the first listed.
NCT05360056 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05360056 about?
NCT05360056 is a clinical study titled "Continuous Glucose Monitoring Following Hospital Discharge". In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completio...
What is the current status of trial NCT05360056?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 108 participants. The study started on 2022-04-26. Estimated completion is 2025-12.
What conditions does trial NCT05360056 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT05360056?
The interventions under investigation include: DexCom G6 (DEVICE).
Who is sponsoring clinical trial NCT05360056?
This trial is sponsored by Kathleen Dungan, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05360056 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05360056's enrollment target sits among peer trials
108 146th of 327 higher than 182 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI